Avelumab is a fully human mAb targeting programmed death ligand 1 (PD-L1) antibody (Figure 6B) with known efficacy in Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. Here, CD274 is linked to urothelial carcinoma.